Xtandi 80 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FJQC8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,422
Award facts
- Contract value 100% obligated
- $4,422.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $4,422.16 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count). This firm fixed-price delivery order, with an ultimate completion date of February 5, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier for Department of Defense healthcare operations, providing a comprehensive range of branded and generic prescription medications, biologics, vaccines, and medical consumables to military healthcare facilities worldwide. The Pharmaceutical Prime Vendor Global Program Generation V represents a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement across the military medical system. The PPV-G GEN V contract structure includes a 30-month base period with three 30-month option periods, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors authorized to fulfill the recurring and specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FJQC8?
SPE2DR26FJQC8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FJQC8 worth?
The government has obligated $4,422 on SPE2DR26FJQC8.
Is contract SPE2DR26FJQC8 an order under another contract?
Yes. SPE2DR26FJQC8 is a delivery order under SPE2DR25D9224, an indefinite delivery contract.
Was contract SPE2DR26FJQC8 competed?
The extent of competition for SPE2DR26FJQC8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award